100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure

Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But why isn't it a cure yet, and how does it fit into the actual blueprint of a functional cure? The post 100% Insulin Independence: Why Eledon’s…